Sonic The Hedgehog 3 June 7 2024
Sergei Chime
With overwhelming demand, SEGA just announced extended tour dates for the Sonic Symphony World Tour. In celebration of 30 years of blessing our childhood eardrums as Sonic comes dashing through, they're bringing its 8 and 16-bit EDM bangers to the live stage. Catch a full symphony orchestra performing live renditions of iconic gameplay and film tunes at Orpheum Theatre Minneapolis at Sonic Symphony Live on Saturday, June 22. It's definitely a whole new sonic experience. Taking audiences on an immersive musical journey starring your favorite hedgehog alongside state-of-the-art visual productions, it's a feast for the senses. It's more than just a blast from the past. It's a Sonic experience like never before. You're even up to relive memorable moments with some real gameplay footage on the big screen. After its first leg of shows, fans have craved for more. Due to popular demand, SEGA is extending its symphony parties, all for Sonic the Hedgehog. Book your tickets now!
Three decades of 8-bit, 16-bit, and EDM notes gracing gameplay and film, the world's most famous hedgehog is coming to the big screen. Nope, it's not a movie... it's a Sonic Symphony featuring a live orchestra playing iconic renditions of the game's tunes and new sonic surprises. In celebration of 30 years of Sonic, SEGA is presenting its newest live stage show - the Sonic Symphony World Tour. Audiences will be immersed in a sonic experience like no other. As the ensemble gracefully pulls its strings, you're in for a treat! A backdrop of exciting and memorable gameplay moments will be projected on the big screen.
It sure does sound like the perfect childhood dream. These days, healing your inner child has been a hot take, and SEGA's celebratory tour is definitely sending us to tears. Straight out of your Gameboy memories, it's a full-on Sonic orchestra! Moreover, new generations of Sonic fans are also bound to enjoy a majestic show with their favorite dashing Hedgehog.
A blast from the past, it's a unique way to celebrate endless memories of the iconic game. After three decades of entertaining and keeping kids, teens, and child-at-hearts pumped up, we couldn't imagine a better way to celebrate this grand milestone.
"Relive your favorite Sonic moments, brought to life by a full symphony orchestra," Sega added. "Sonic Symphony will be an electrifying tribute to the music that has defined generations of gamers, old and new."
An electrifying tribute. Blessing our ears with quirky tunes in the 8-bit, 16-bit, and EDM world, SEGA's symphony is a unique experience that everyone, no matter what age, will surely cherish. With trademark soundtracks in every game including rock, funk, rap, and jazzy loops, Sonic's history is full of earworms. Our favorites include "Live and Learn" and "Escape from the City" off of Sonic Adventure 2. Celebrating its impact through the power of music, we're all in!
As its pixels continue to grow, Sonic's legacy is here to stay. Having been part of children's lives one way or another, it's definitely something worth celebrating. 30 years of Sonic, live at Orpheum Theatre Minneapolis on June 22. Book your tickets now!
Introduction: Basal cell carcinoma (BCC) is the most common skin malignancy in the world. While most lesions are treated using surgical methods, others may present as locally advanced or metastatic disease and are not amenable to surgical therapy alone. Treatment with sonic hedgehog pathway inhibitors (vismodegib, sonidegib) is designed to inhibit key signaling proteins and gene pathways involved with BCC to reduce the uncontrolled proliferation of basal cells in complicated disease and can be invaluable in treating patients with advanced disease. Case Presentation: We describe the course of a 68-year-old man who presented with a 7.2 6 cm exophytic and ulcerated locally invasive BCC of his upper back. The patient was started on daily vismodegib treatment with the goal of eventual surgical resection. After 11 weeks of therapy, he had significant improvement in both wound size and appearance. After 18 weeks of therapy, he had achieved a near complete clinical response of the central aspect of lesion with three remaining small peripheral lesions. These lesions were biopsied, and two were found to be negative for malignancy, while a small inferior nodule was positive for squamous cell carcinoma (SCC). Vismodegib therapy was discontinued after a total of 26 weeks of therapy. Excision of the SCC was performed, and the patient remains disease free at 2 years. Conclusion: This case report shows the efficacy of hedgehog pathway inhibitor therapy in the treatment of a locally advanced BCC with complete pathologic response, not requiring surgical intervention.
Basal cell carcinoma (BCC) is the most common cutaneous malignancy in the USA and worldwide [1]. In the USA, more than 2.8 million cases are diagnosed each year. BCC is commonly located on the head and neck, as it occurs when ultraviolet radiation causes DNA damage to sun-exposed skin [2]. Ultraviolet exposure damages the tumor surveillance function of the cutaneous immune system and the activity of tumor suppressor genes, which promotes the growth and advancement of BCC [3, 4]. In cases of sporadic BCC, over 90% were found to have molecular alterations in the hedgehog signaling pathway which involves transmembrane protein patched homologue 1 and the binding to extracellular ligand smoothened homologue (SMO) [3, 5, 6]. BCC is typically stratified as low risk versus high risk based on several clinical criteria including tumor size, location, histologic pattern, and recurrence status [6]. As BCC generally has low potential to metastasize, clinical management is primarily focused on the risk of subclinical tumor infiltration and local recurrence. Low-risk BCC may be amenable to standard excision or ablative treatment with electrodessication and curettage. For patients who are not candidates for surgery, primary radiation or topical therapies with 5% imiquimod or 5% fluorouracil can be delivered with acceptable cure rates [6].
High-risk BCC is best managed with surgical techniques that include complete peripheral and deep margin assessment, either surgical excision with subsequent pathologic assessment of margins or Mohs micrographic surgery. Mohs surgery includes micrographic assessment of margins during surgery to further precisely direct the extent of resection. For BCC of the face, a randomized clinical trial comparing standard excision versus Mohs surgery found lower recurrence rates at 10 years for both primary and recurrent BCC of the face treated with Mohs surgery [7].
A 68-year-old man with medical history of hypertension, coronary artery disease, ischemic cardiomyopathy, and atrial fibrillation was initially evaluated in the dermatology clinic for a large exophytic, fungating lesion located on his upper mid-back. The patient was hospitalized 12 months prior for an episode of heart failure, when the lesion was first documented (Fig. 1a) and biopsy showed angulated nests of BCC in an infiltrative pattern. He was referred for outpatient follow-up with a surgeon for planned surgical resection.
The patient completed a total of 26 weeks of vismodegib therapy. Six weeks after discontinuation, a Mohs excision of the SCC nodule was performed. The frozen section showed a one-layer, 2.4-cm defect with no evidence of BCC and clear margins for squamous cell. Follow-up, 14 weeks after discontinuing therapy, in clinic (Fig. 3b) and subsequent surveillance visits at one and 2 years have demonstrated no evidence of local recurrence.
Studies of molecular signaling pathways in a large majority of BCC have shown genetic alterations in the hedgehog signaling pathway [3]. These alterations result in the activation and uncontrolled proliferation of basal cells leading to the development and progression of both metastatic and locally advanced BCC [15]. The most common mutation is the loss of function of patched homologue 1 which inhibits the transmembrane protein SMO. Sonic hedgehog pathway inhibitors function by inhibiting SMO which in turn blocks activation of glioma-associated oncogenes (GLP-1) that are responsible for tumor progression [18]. Currently, two medications are approved by the US Food and Drug Administration (FDA) in this class of medication, vismodegib (indicated for locally advanced and metastatic BCC) and sonidegib (indicated for locally advanced BCC only). In this clinical scenario, sonidegib was not an option for this patient due to lack of insurance formulary coverage. No head-to-head clinical trials have been completed to date between the two medications, but emerging evidence published after this clinical encounter may indicate high efficacy in treating aggressive pathological BCC subtypes and a lower risk of side effects with sonidegib [19]. In the landmark clinical trial conducted on patients with locally advanced BCC, 54% of patients demonstrated no residual disease on biopsy of target BCC lesions after treatment with vismodegib. Furthermore, significant reduction in tumor size was observed in this initial study reporting clinical efficacy for locally advanced or metastatic BCC [15]. Subsequent meta-analysis for locally advanced or metastatic BCC has also demonstrated a tremendous objective response rate of 64.7% and a remarkable complete response rate of 31.1% [12]. Median duration of therapy was 35 weeks, slightly longer than the 26 weeks our patient was on therapy. There are, however, notable side effects for patients on vismodegib therapy that may present challenges with compliance. These include fatigue, loss of appetite, alopecia, diarrhea, muscle spasms, impaired taste, and weight loss. Due to these side effects, many patients are unable to tolerate the treatment, and Jacobsen et al. found that more than a quarter of their patients (28.2%) discontinued therapy [1, 12, 15]. Our patient developed alopecia, but was willing to continue therapy.
c80f0f1006